by NImmune Biopharma | Oct 13, 2026 | Press Release
New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ulcerative colitis and Crohn’s disease patients Omilancor and NIM-1324 reduced disease severity, pathology and recurrence in models of IBD and...
by NImmune Biopharma | Oct 12, 2026 | Press Release
Download Press Release New data presented at ACG 2026 demonstrates LANCL2 mechanism targets can reverse expression patterns associated with refractoriness in biologic failure IBD patients NIM-1324 reduces severity of IBD and Clostridiodes difficile symptoms during...
by NImmune Biopharma | May 5, 2026 | Press Release
Download Press Release New data presented at DDW demonstrates that NIM-1324 outperforms current IBD medications, establishes Phase 1 safety, tolerability and LANCL2 target engagement in humans Supports the efficacy of NIM-1324, a de-risked, safe and well-tolerated,...
by NImmune Biopharma | Apr 20, 2026 | Research and White Papers
NImmune Biopharma, Inc is pleased to share the release of exciting new data on the efficacy of LANCL2 medicines in treating inflammatory diseases and their immunometabolic mechanisms of action at The American Association of Immunologists Annual Meeting,...
by NImmune Biopharma | Mar 24, 2026 | Press Release
Download Press Release Novel findings to be presented at IMMUNOLOGY2026 demonstrate efficacy of novel LANCL2-targeting therapeutics outperforming current psoriasis treatments in multiple mouse models Newly discovered mechanisms in phagocytes and epithelial cells in...
